SNMMI will advocate for CMS to reimburse PET imaging for Aduhelm use


SNMMI said it will advocate for the CMS to cover beta amyloid PET imaging for Biogen's newly approved Alzheimer's disease drug Aduhelm, or aducanumab. Amyloid PET scans are currently not included on Aduhelm's label as a requirement for prescribing the drug, but positive beta-amyloid PET scans were among major inclusion criteria in the trials that resulted in Aduhelm's approval, SNMMI noted.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.